Page 70 - Read Online

Page 138 Chalatsa et al. Neuroimmunol Neuroinflammation 2020;7:132-40 I http://dx.doi.org/10.20517/2347-8659.2020.01

10. Simón-Sánchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, et al. Genome-wide association study reveals genetic risk underlying
Parkinson’s disease. Nat Genet 2009;41:1308-12.
11. Emamzadeh FN, Surguchov A. Parkinson’s disease: biomarkers, treatment, and risk factors. Front Neurosci 2018;12:612.
12. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, et al. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat
Cell Biol 2002;4:160-4.
13. Paleologou KE, Kragh CL, Mann DM, Salem SA, Al-Shami R, et al. Detection of elevated levels of soluble alpha-synuclein oligomers in
post-mortem brain extracts from patients with dementia with Lewy bodies. Brain 2009;132:1093-101.
14. Surguchov A. Parkinson’s disease: assay of phosphorylated alpha-synuclein in skin biopsy for early diagnosis and association with
melanoma. Brain Sci 2016;6.
15. Mollenhauer B, Bowman FD, Drake D, Duong J, Blennow K, et al. Antibody-based methods for the measurement of α-synuclein
concentration in human cerebrospinal fluid - method comparison and round robin study. J Neurochem 2019;149:126-38.
16. Magdalinou N, Lees AJ, Zetterberg H. Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions. J
Neurol Neurosurg Psychiatry 2014;85:1065-75.
17. Eusebi P, Hansson O, Paciotti S, Orso M, Chiasserini D, et al. Cerebrospinal fluid biomarkers for the diagnosis and prognosis of
Parkinson’s disease: protocol for a systematic review and individual participant data meta-analysis. BMJ Open 2017;7:e018177.
18. Mollenhauer B, Caspell-Garcia CJ, Coffey CS, Taylor P, Singleton A, et al. Longitudinal analyses of cerebrospinal fluid α-Synuclein in
prodromal and early Parkinson’s disease. Mov Disord 2019;34:1354-64.
19. Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of
Parkinson’s disease. Brain 2010;133:713-26.
20. Mollenhauer B, Cullen V, Kahn I, Krastins B, Outeiro TF, et al. Direct quantification of CSF alpha-synuclein by ELISA and first cross-
sectional study in patients with neurodegeneration. Exp Neurol 2008;213:315-25.
21. van Dijk KD, Bidinosti M, Weiss A, Raijmakers P, Berendse HW, et al. Reduced α-synuclein levels in cerebrospinal fluid in Parkinson’s
disease are unrelated to clinical and imaging measures of disease severity. Eur J Neurol 2014;21:388-94.
22. Kruse N, Mollenhauer B. Quantification of alpha-synuclein in biological fluids by electrochemiluminescence-based detection. Methods
Mol Biol 2019;1948:59-68.
23. Borghi R, Marchese R, Negro A, Marinelli L, Forloni G, et al. Full length alpha-synuclein is present in cerebrospinal fluid from
Parkinson’s disease and normal subjects. Neurosci Lett 2000;287:65-7.
24. Saijo E, Groveman BR, Kraus A, Metrick M, Orrù CD, et al. Ultrasensitive RT-QuIC seed amplification assays for disease-associated tau,
α-synuclein, and prion aggregates. Methods Mol Biol 2019;1873:19-37.
25. Shahnawaz M, Mukherjee A, Pritzkow S, Mendez N, Rabadia P, et al. Discriminating alpha-synuclein strains in Parkinson’s disease and
multiple system atrophy. Nature 2020;578:273-7.
26. Shahnawaz M, Tokuda T, Waragai M, Mendez N, Ishii R, et al. Development of a biochemical diagnosis of Parkinson disease by
detection of α-synuclein misfolded aggregates in cerebrospinal fluid. JAMA Neurol 2017;74:163-72.
27. Park MJ, Cheon SM, Bae HR, Kim SH, Kim JW. Elevated levels of α-synuclein oligomer in the cerebrospinal fluid of drug-naïve patients
with Parkinson’s disease. J Clin Neurol 2011;7:215-22.
28. Ohrfelt A, Grognet P, Andreasen N, Wallin A, Vanmechelen E, et al. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a
marker of synapse loss. Neurosci Lett 2009;450:332-5.
29. Aerts MB, Esselink RA, Abdo WF, Bloem BR, Verbeek MM. CSF α-synuclein does not differentiate between parkinsonian disorders.
Neurobiol Aging 2012;33:430.e1-3.
30. García-Ayllón MS, Monge-Argilés JA, Monge-García V, Navarrete F, Cortés-Gómez MA, et al. Measurement of CSF α-synuclein
improves early differential diagnosis of mild cognitive impairment due to Alzheimer’s disease. J Neurochem 2019;150:218-30.
31. Twohig D, Rodriguez-Vieitez E, Sando SB, Berge G, Lauridsen C, et al. The relevance of cerebrospinal fluid α-synuclein levels to
sporadic and familial Alzheimer’s disease. Acta Neuropathol Commun 2018;6:130.
32. Oeckl P, Metzger F, Nagl M, von Arnim CA, Halbgebauer S, et al. Alpha-, beta-, and gamma-synuclein quantification in cerebrospinal
fluid by multiple reaction monitoring reveals increased concentrations in Alzheimer’s and Creutzfeldt-Jakob disease but no alteration in
synucleinopathies. Mol Cell Proteomics 2016;15:3126-38.
33. Katayama T, Sawada J, Kikuchi-Takeguchi S, Kano K, Takahashi K, et al. Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau,
phosphorylated tau, and neuron-specific enolase in patients with Parkinson’s disease, dementia with Lewy bodies or other neurological
disorders: their relationships with cognition and nuclear medicine imaging findings. Neurosci Lett 2019;715:134564.
34. Bougea A, Stefanis L, Paraskevas GP, Emmanouilidou E, Efthymiopoulou E, et al. Neuropsychiatric symptoms and α-Synuclein profile
of patients with Parkinson’s disease dementia, dementia with Lewy bodies and Alzheimer’s disease. J Neurol 2018;265:2295-301.
35. Bongianni M, Ladogana A, Capaldi S, Klotz S, Baiardi S, et al. α-Synuclein RT-QuIC assay in cerebrospinal fluid of patients with
dementia with Lewy bodies. Ann Clin Transl Neurol 2019;6:2120-6.
36. Lerche S, Wurster I, Roeben B, Zimmermann M, Riebenbauer B, et al. Parkinson’s disease: glucocerebrosidase 1 mutation severity is
associated with CSF alpha-synuclein profiles. Mov Disord 2020;35:495-9.
37. Viodé A, Epelbaum S, Benyounes I, Verny M, Dubois B, et al. Simultaneous quantification of tau and α-synuclein in cerebrospinal
fluid by high-resolution mass spectrometry for differentiation of Lewy Body Dementia from Alzheimer’s disease and controls. Analyst
2019;144:6342-51.
38. Shi M, Tang L, Toledo JB, Ginghina C, Wang H, et al. Cerebrospinal fluid α-synuclein contributes to the differential diagnosis of
Alzheimer’s disease. Alzheimers Dement 2018;14:1052-62.